Trials / Completed
CompletedNCT01859026
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to find out if the drugs MEK162 and erlotinib (Tarceva) given in combination are safe and have beneficial effects in patients who have NSCLC. The U.S. Food and Drug Administration (FDA) has not approved MEK162 for use to treat NSCLC. Erlotinib is an FDA approved drug for the treatment of Non-Small Cell Lung Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEK162 | Treatment as outlined in study arms. |
| DRUG | Erlotinib | Treatment as outlined in study arms. |
Timeline
- Start date
- 2013-12-30
- Primary completion
- 2019-08-22
- Completion
- 2019-08-22
- First posted
- 2013-05-21
- Last updated
- 2023-01-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01859026. Inclusion in this directory is not an endorsement.